Granite Bay Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Granite Bay Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454K	Buy	915 +5	+0.5%	+$2.22K	0.04%	123
2026 Q1	$407K	Buy	910 +8	+0.9%	+$3.73K	0.09%	60
2025 Q4	$409K	Buy	902 +2	+0.2%	+$862	0.1%	58
2025 Q3	$352K	Hold	900	–	–	0.09%	57
2025 Q2	$401K	Buy	900 +300	+50%	+$138K	0.13%	45
2025 Q1	$291K	Sell	600 -304	-34%	-$142K	0.1%	59
2024 Q4	$364K	Buy	904 +4	+0.4%	+$1.85K	0.13%	53
2024 Q3	$419K	Hold	900	–	–	0.24%	31
2024 Q2	$422K	Hold	900	–	–	0.23%	42
2024 Q1	$376K	Buy	+900	New	+$380K	0.21%	56
2023 Q2	$211K	Buy	+600	New	+$202K	0.2%	42
2022 Q2	–	Sell	-810	Closed	-$211K	–	62
2022 Q1	$211K	Sell	810 -190	-19%	-$45.1K	0.17%	58
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.22%	57

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Granite Bay Wealth Management's VRTX Position: Q2 2026 in Review

Granite Bay Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.55% in Q2 2026, buying an estimated $2.22K and bringing the position to 915 shares worth $454K. The position accounts for 0.04% of the portfolio, ranked #123.

Granite Bay Wealth Management first reported a position in VRTX in Q4 2021 and has held it in 13 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Granite Bay Wealth Management held 915 shares of Vertex Pharmaceuticals worth $454K as of Q2 2026.
Granite Bay Wealth Management bought 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
Vertex Pharmaceuticals made up 0.04% of Granite Bay Wealth Management's portfolio in Q2 2026, its #123 holding.
Granite Bay Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Granite Bay Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.